Single payer universal healthcare: my campaign takeaways

Both labeled "Medicare for All Act." Both promising universal coverage. Neither has cleared a single committee. That distance — between the slogan echoing through a rally microphone and the legislative reality sitting in referral boxes across seven House committees — is the single most important thing any healthcare organizer needs to grasp right now.

I spent the last campaign cycle doing the work that does not make the press releases. Knocking doors, building precinct lists, watching volunteers learn the hard way what the bills actually say versus what the fundraising copy claims they say. We won some arguments. We lost a few we should have closed. These are the field notes — not from a podium, not from a foundation retreat, but from the ground.

The Legislative Gap: From Rally Rhetoric to H.R. 3069

The campaign language is simple: pass Medicare for All. The legislative language is not. H.R. 3069 is a 130-plus-page statute that restructures how every American interacts with the healthcare system — what they pay at the point of service, what their employer is permitted to offer, what an insurance company is allowed to sell. Treating it as a single sentence is how opponents neutralize it and how supporters oversell it.

The retrieved Congress.gov record lists 111 current cosponsors for H.R. 3069 and shows the bill referred to seven House committees. No CBO cost estimate is attached. That detail alone should disqualify any number circulating online as "the price tag" of the bill. We do not yet have an official score. Anyone claiming a definitive household-level financial impact — for or against — is fabricating precision the legislative process has not produced.

The bill is real. The cost figure floating around your group chat is not.

The strategic mistake I watched repeatedly last cycle: volunteers treated cosponsor counts and rally attendance as proxies for legislative momentum. They are not. Cosponsorships are low-cost political signals. Committee referrals are the actual gate. Until the House Energy and Commerce Committee, the Ways and Means Committee, and the rest of the referral stack mark up the bill, the document is a marker on the field, not a runner.

Defining the Goal: Universal Coverage Is Not a Financing Model

Here is the terminology trap that costs campaigns votes: the conflation of universal health coverage, Medicare for All, and single payer as if they were the same object. They are not.

The World Health Organization defines universal health coverage as access to needed quality health services without financial hardship — and explicitly notes that affordability can be achieved through different financing arrangements. That is an outcome. Single payer is one specific financing architecture that could, in principle, deliver that outcome. Other countries reach comparable coverage through multi-payer social insurance, regulated private systems, or hybrid models. The campaign we ran was for a particular design. The moral case is for the outcome.

This matters because the moment a door-knocker concedes "any universal system works," the structural argument collapses. If we cannot articulate why a single federal risk pool with public financing produces different material conditions than, say, a robust public option layered onto employer-sponsored insurance, we have already conceded the architecture debate. And the architecture is the entire fight.

For the 2024 reporting year, 92.0% of the U.S. population — 310 million people — had health insurance for some or all of the year. That sounds like a near-universal system until you see the other figure: 27.1 million people, 8.0% of the population, were uninsured for the entire year. Coverage depth, continuity, and out-of-pocket exposure are where the system fails. The 8% is not the only problem. The 92% includes people with $7,000 deductibles, people whose insurer denied a claim last Tuesday, people one job loss away from total exposure.

The Cost-Sharing Divide: Comparing House and Senate Approaches

Volunteers on the trail confidently told voters the two bills are identical. They are not. Anyone running a campaign for single payer universal healthcare who cannot explain the cost-sharing difference between H.R. 3069 and S. 1506 is doing the movement a disservice.

The House bill, H.R. 3069, would bar deductibles, coinsurance, copayments, and similar charges for covered benefits. It would also prohibit balance billing for covered services. That is the cleanest version of the policy: at the point of service, the patient pays nothing for what the program covers.

The Senate companion, S. 1506, permits limited prescription-drug cost-sharing — no more than $200 per individual annually, adjusted for inflation, with preventive drugs exempted and households at or below 250% of the poverty line exempted as well. A small dollar figure. A meaningful structural distinction.

That table is not trivia. It tells voters what the system will actually look like at the pharmacy counter. It tells opponents exactly where to attack. It tells labor unions which version protects their negotiated drug benefits and which version dissolves them. Running a campaign that pretends the two bills are interchangeable forfeits credibility on every front.

Transition Mechanics: Eligibility Tiers and Protecting Ongoing Care

Here is where the campaign rhetoric and the bill text diverge most dangerously. The slogan promises universal coverage on day one. The House bill does not. Under H.R. 3069, full program benefits would begin two years after enactment. One year after enactment, the bill would extend eligibility to people aged 18 or younger and people aged 55 or older. Everyone else waits.

That sequencing exists for a reason. A single-payer system cannot onboard 330 million people overnight without collapsing the provider network. The eligibility tiers are the bill's acknowledgment of material constraints — workforce capacity, claims-processing infrastructure, hospital revenue cycles that cannot absorb a half-trillion-dollar payment restructuring in a single quarter.

The bill also requires protections against disruption of ongoing care during the transition. That language matters. Anyone with a cancer regimen, a dialysis schedule, a long-term prescription for a controlled substance knows what "disruption of ongoing care" looks like in practice. The bill attempts to insulate them. Whether those protections are enforceable — whether a regional hospital facing a 30% revenue shock will honor them — is a question the legislative text does not answer. It is also a question we cannot answer honestly without acknowledging that transition design is where most prior single-payer proposals have died.

For organizers, the takeaway is direct: do not promise day-one universality on the doors. Promise the eligibility tiers. Promise the transition protections. Promise what the bill actually does. Voters can handle sequencing. They cannot handle a broken promise made before the policy was understood.

The $5.3 Trillion Reality: Navigating the Obstacles

U.S. national health expenditures reached $5.3 trillion in 2024. That is $15,474 per person. That is 18.0% of GDP. Out-of-pocket spending alone hit $556.6 billion — 11% of total national health expenditures. These are CMS figures, not advocacy projections.

The scale is the obstacle. The scale is also the argument. No serious restructuring can be financed without taking on the extraction embedded in those numbers. The campaign that pretends single payer adds zero cost to the federal ledger is the campaign that hands opponents a free shot. The campaign that pretends the existing $5.3 trillion is efficiently allocated is the campaign that has not read the medical billing literature.

What we can say with confidence: the current system spends $15,474 per person and still leaves 27.1 million people uninsured for the full year and millions more functionally underinsured. What we cannot say with confidence: that any particular single-payer design will reduce total spending, eliminate every access barrier, preserve every existing provider relationship, or deliver a specific outcome without a defined model and a scored projection. The retrieved sources do not establish those guarantees. Anyone making them is selling, not analyzing.

The political extraction problem is not separate from the spending problem. The same structural actors who profit from the $5.3 trillion flow — private insurers, hospital systems, pharmaceutical manufacturers, the lobbying infrastructure that protects them — are the actors with the leverage to keep H.R. 3069 and S. 1506 parked in committee. Complicity is bipartisan when enough money is on the table.

What the Field Demands Next

We are not short on volunteers. We are not short on rally energy. We are short on legislative literacy — and the opposition is betting on that.

A serious single-payer campaign in the current Congress has to do four things the last cycle mostly avoided. First, train every canvasser on the actual bill text, including the cost-sharing difference between the House and Senate versions. Second, stop manufacturing cost figures that have no CBO score behind them and start demanding one. Third, build the transition argument with workers, hospitals, and patients whose lives depend on continuity, not just with the people who already agree. Fourth, treat committee markups as the campaign's actual target — not the floor vote, not the signing ceremony, but the moment the bill is rewritten or buried by the subcommittee chairs who answer to the extraction economy.

The bill is in committee. The fight is in committee. Everything else is theater until that changes.

The work is unglamorous. The work is what actually moves $5.3 trillion of extraction out of the hands that hoard it. We have done the easier part. We have not yet done this part.